Intracellular Zinc-Dependent TAS2R8 Gene Expression Through CTCF Activa- Tion
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Genetic Association with Overall Survival of Taxane-Treated Lung
Genetic association with overall survival of taxane-treated lung cancer patients - a genome-wide association study in human lymphoblastoid cell lines followed by a clinical association study The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters. Citation Niu, Nifang et al. “Genetic Association with Overall Survival of Taxane-treated Lung Cancer Patients - a Genome-wide Association Study in Human Lymphoblastoid Cell Lines Followed by a Clinical Association Study.” BMC Cancer 12.1 (2012): 422. CrossRef. Web. As Published http://dx.doi.org/10.1186/1471-2407-12-422 Publisher BioMed Central Ltd. Version Final published version Citable link http://hdl.handle.net/1721.1/77191 Terms of Use Creative Commons Attribution Detailed Terms http://creativecommons.org/licenses/by/2.0 Genetic variations and paclitaxel response Supplementary Figure 1. Imputation analysis for 8 SNPs associated with both paclitaxel IC50 in LCLs and overall survival in lung cancer patients. SNPs within 200kb up-/downstream of those 8 SNPs were imputed. Black circles indicate SNPs observed by genotyping, while red triangles indicate imputed SNPs. The y-axis represents –log10(p-value) for the association of each SNP with paclitaxel IC50, and the x-axis represents the chromosomal locations of the SNPs. Genetic variations in paclitaxel response 1 Supplementary Table 1. Top 1415 SNPs that were associated with paclitaxel IC50 with p-values <10-3 and top 147 SNPs that were significantly associated with paclitaxel IC50 -
Ep 2329271 B1
(19) & (11) EP 2 329 271 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: G01N 33/566 (2006.01) G01N 33/50 (2006.01) 20.06.2012 Bulletin 2012/25 (86) International application number: (21) Application number: 09775777.7 PCT/CH2009/000290 (22) Date of filing: 27.08.2009 (87) International publication number: WO 2010/022529 (04.03.2010 Gazette 2010/09) (54) METHODS TO IDENTIFY MODULATORS VERFAHREN ZUR IDENTIFIZIERUNG VON MODULATOREN PROCÉDÉS D’IDENTIFICATION DE MODULATEURS (84) Designated Contracting States: • EVANS PENNIMPEDE, Jenny Ellen AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Cincinnati, OH 45241 (US) HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR (74) Representative: Simmons, John Murray Givaudan Schweiz AG (30) Priority: 29.08.2008 US 92839 P Global Patents Überlandstrasse 138 (43) Date of publication of application: 8600 Dübendorf (CH) 08.06.2011 Bulletin 2011/23 (56) References cited: (73) Proprietor: Givaudan SA WO-A2-2006/053771 WO-A2-2006/086150 1214 Vernier (CH) WO-A2-2007/011859 US-A1- 2004 214 239 US-A1- 2008 038 739 (72) Inventors: • SLACK, Jay, Patrick Loveland, OH 45140 (US) Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. -
(12) United States Patent (10) Patent No.: US 9,347,934 B2 Shekdar Et Al
USOO9347934B2 (12) United States Patent (10) Patent No.: US 9,347,934 B2 Shekdar et al. (45) Date of Patent: May 24, 2016 (54) ASSAYS FOR IDENTIFYING COMPOUNDS 2008, OO38739 A1 2/2008 Li et al. THAT MODULATE BITTERTASTE 2008/0167286 A1* 7/2008 Gopalakrishnan et al. ........................ 514,21016 (71) Applicants: CHROMOCELL CORPORATION, 2010/01298.33 A1* 5/2010 Brune et al. ................. 435/721 North Brunswick, NJ (US); KRAFT FOODS GROUP BRANDS LLC, FOREIGN PATENT DOCUMENTS Northfield, IL (US) CN 1341632 A 3, 2002 CN 101583717 A 11, 2009 (72) Inventors: Kambiz Shekdar, New York, NY (US); CN 101828.111 A 9, 2010 Purvi Manoj Shah, Bridgewater, NJ WO WO-0038536 A2 7, 2000 WO WO-2004O29087 4/2004 (US); Joseph Gunnet, Flemington, NJ WO WO-2006053771 A2 5, 2006 (US); Jane V. Leland, Wilmette, IL WO WO-2007002026 A2 1/2007 (US); Peter H. Brown, Glenview, IL WO WO-2008057470 5, 2008 (US); Louise Slade, Morris Plains, NJ WO WO-2008119.195 A1 10, 2008 (US) WO WO-20081191.96 10, 2008 WO WO-20081191.97 10, 2008 (73) Assignees: Chromocell Corporation, North W WSi. A2 1929 Brunswick, NJ (US); Kraft Foods WO WO-2010O886.33 8, 2010 Group Brands LLC, Northfield, IL WO WO-2010O99983 A1 9, 2010 (US) WO WO-2013022947 2, 2013 (*) Notice: Subject to any disclaimer, the term of this OTHER PUBLICATIONS patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days. Bachmanov et al., Taste Receptor Genes, 2007, 27:389-414.* Behrens et al., Structural Requirements for Bitter Taste Receptor (21) Appl. -
G Protein-Coupled Receptors
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. British Journal of Pharmacology (2015) 172, 5744–5869 THE CONCISE GUIDE TO PHARMACOLOGY 2015/16: G protein-coupled receptors Stephen PH Alexander1, Anthony P Davenport2, Eamonn Kelly3, Neil Marrion3, John A Peters4, Helen E Benson5, Elena Faccenda5, Adam J Pawson5, Joanna L Sharman5, Christopher Southan5, Jamie A Davies5 and CGTP Collaborators 1School of Biomedical Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK, 2Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK, 3School of Physiology and Pharmacology, University of Bristol, Bristol, BS8 1TD, UK, 4Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK, 5Centre for Integrative Physiology, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2015/16 provides concise overviews of the key properties of over 1750 human drug targets with their pharmacology, plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. The full contents can be found at http://onlinelibrary.wiley.com/doi/ 10.1111/bph.13348/full. G protein-coupled receptors are one of the eight major pharmacological targets into which the Guide is divided, with the others being: ligand-gated ion channels, voltage-gated ion channels, other ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading. -
G Protein‐Coupled Receptors
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: G protein-coupled receptors. British Journal of Pharmacology (2019) 176, S21–S141 THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors Stephen PH Alexander1 , Arthur Christopoulos2 , Anthony P Davenport3 , Eamonn Kelly4, Alistair Mathie5 , John A Peters6 , Emma L Veale5 ,JaneFArmstrong7 , Elena Faccenda7 ,SimonDHarding7 ,AdamJPawson7 , Joanna L Sharman7 , Christopher Southan7 , Jamie A Davies7 and CGTP Collaborators 1School of Life Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK 2Monash Institute of Pharmaceutical Sciences and Department of Pharmacology, Monash University, Parkville, Victoria 3052, Australia 3Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK 4School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, BS8 1TD, UK 5Medway School of Pharmacy, The Universities of Greenwich and Kent at Medway, Anson Building, Central Avenue, Chatham Maritime, Chatham, Kent, ME4 4TB, UK 6Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK 7Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide represents approximately 400 pages, the material presented is substantially reduced compared to information and links presented on the website. -
Origins and Adaptation in Humans: a Case Study of Taste and Lifestyle
Origins and adaptation in humans : a case study of taste and lifestyle Agnès Sjöstrand To cite this version: Agnès Sjöstrand. Origins and adaptation in humans : a case study of taste and lifestyle. Human genetics. Université Pierre et Marie Curie - Paris VI; Uppsala universitet, 2015. English. NNT : 2015PA066724. tel-01609900 HAL Id: tel-01609900 https://tel.archives-ouvertes.fr/tel-01609900 Submitted on 4 Oct 2017 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Université Pierre et Marie Curie Université d’Uppsala ED227 : Sciences de la Nature et de l’Homme : Écologie et Évolution UMR7206 Eco-Anthropologie et Ethnobiologie, Evolutionary Biology Center (Uppsala University) UMR5525 Laboratoire TIMC-IMAG. Origins and Adaptation in Humans a Case Study of Taste and Lifestyle Par Agnès Sjöstrand Thèse de doctorat de Génétique des populations Dirigée par Pr. Evelyne Heyer, Pr. Mattias Jakobsson & Dr. Michael Blum Présentée et soutenue publiquement le 20 novembre 2015 Devant un jury composé de : David Comas, professeur (rapporteur) Luis Quintana-Murci, directeur de recherche (rapporteur) Thierry Wirth, professeur (examinateur) Denis Pierron, chargé de recherche (examinateur) Åsa Johansson, chercheuse (examinatrice) Evelyne Heyer, professeure (directrice de thèse) Mattias Jakobsson, professeur (directeur de thèse) Michaël Blum, directeur de recherche (co-directeur de thèse) Ubuntu (Nguni word) Shosholoza (Ndebele word) List of Papers This thesis is based on the following papers, which are referred to in the text by their Roman numerals. -
Genetic Variations in TAS2R3 and TAS2R4 Bitterness Receptors Modify
www.nature.com/scientificreports OPEN Genetic variations in TAS2R3 and TAS2R4 bitterness receptors modify papillary carcinoma risk and Received: 10 January 2018 Accepted: 25 September 2018 thyroid function in Korean females Published: xx xx xxxx Jeong-Hwa Choi 1,2, Jeonghee Lee 1, Sarah Yang1,3, Eun Kyung Lee4, Yul Hwangbo4 & Jeongseon Kim 1 Type 2 taste receptors (T2Rs, TAS2Rs) mediate bitterness perception and are involved in diverse defence mechanisms in extraoral tissues. The thyrocyte-expressed T2Rs control thyroid hormone production, and this regulatory role may be associated with susceptibility to thyroid diseases. This study examined whether the variations in TAS2Rs modify the risk of papillary thyroid carcinoma (PTC) and whether such T2R-related PTC risk is associated with genetically modifed thyroid function. We conducted a case-control study with 763 Korean females, including 250 PTC cases. Seventy-three single-nucleotide polymorphisms in 13 TAS2R genes and the pre-diagnosis levels of 4 thyroid-related functional markers [total triiodothyronine (TT3), free thyroxine, thyroid-stimulating hormone and thyroglobulin] were analysed. Individuals with TAS2R3/4 CC haplotype (rs2270009 and rs2234001) were at a lower risk for PTC than those with the remaining haplotypes (odds ratio = 0.59, 95% confdence interval: 0.36–0.97). Furthermore, TT3 levels were signifcantly reduced for TAS2R3/4 CC haplotype carriers compared with other haplotype carriers (p = 0.005). No other genetic variants exhibited critical associations with the PTC phenotype and biomarkers. In summary, genetic variations in T2R3/4 bitterness receptors may modify the PTC risk, and the genetically modifed thyroid hormone level by those variations may be linked with the PTC-T2Rs association. -
The Bitter Taste Receptor Tas2r14 Is Expressed in Ovarian Cancer and Mediates Apoptotic Signalling
THE BITTER TASTE RECEPTOR TAS2R14 IS EXPRESSED IN OVARIAN CANCER AND MEDIATES APOPTOTIC SIGNALLING by Louis T. P. Martin Submitted in partial fulfilment of the requirements for the degree of Master of Science at Dalhousie University Halifax, Nova Scotia June 2017 © Copyright by Louis T. P. Martin, 2017 DEDICATION PAGE To my grandparents, Christina, Frank, Brenda and Bernie, and my parents, Angela and Tom – for teaching me the value of hard work. ii TABLE OF CONTENTS LIST OF TABLES ............................................................................................................. vi LIST OF FIGURES .......................................................................................................... vii ABSTRACT ....................................................................................................................... ix LIST OF ABBREVIATIONS AND SYMBOLS USED .................................................... x ACKNOWLEDGEMENTS .............................................................................................. xii CHAPTER 1 INTRODUCTION ........................................................................................ 1 1.1 G-PROTEIN COUPLED RECEPTORS ................................................................ 1 1.2 GPCR CLASSES .................................................................................................... 4 1.3 GPCR SIGNALING THROUGH G PROTEINS ................................................... 6 1.4 BITTER TASTE RECEPTORS (TAS2RS) ........................................................... -
G Protein-Coupled Receptors
Alexander, S. P. H., Christopoulos, A., Davenport, A. P., Kelly, E., Marrion, N. V., Peters, J. A., Faccenda, E., Harding, S. D., Pawson, A. J., Sharman, J. L., Southan, C., Davies, J. A. (2017). THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: G protein-coupled receptors. British Journal of Pharmacology, 174, S17-S129. https://doi.org/10.1111/bph.13878 Publisher's PDF, also known as Version of record License (if available): CC BY Link to published version (if available): 10.1111/bph.13878 Link to publication record in Explore Bristol Research PDF-document This is the final published version of the article (version of record). It first appeared online via Wiley at https://doi.org/10.1111/bph.13878 . Please refer to any applicable terms of use of the publisher. University of Bristol - Explore Bristol Research General rights This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/ S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2017/18: G protein-coupled receptors. British Journal of Pharmacology (2017) 174, S17–S129 THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: G protein-coupled receptors Stephen PH Alexander1, Arthur Christopoulos2, Anthony P Davenport3, Eamonn Kelly4, Neil V Marrion4, John A Peters5, Elena Faccenda6, Simon D Harding6,AdamJPawson6, Joanna L Sharman6, Christopher Southan6, Jamie A Davies6 and CGTP Collaborators 1 School of Life Sciences, -
Inhibition of Bitter Taste from Oral Tenofovir Alafenamide S
Supplemental material to this article can be found at: http://molpharm.aspetjournals.org/content/suppl/2021/04/06/molpharm.120.000071.DC1 1521-0111/99/5/319–327$35.00 https://doi.org/10.1124/molpharm.120.000071 MOLECULAR PHARMACOLOGY Mol Pharmacol 99:319–327, May 2021 Copyright ª 2021 The Author(s). This is an open access article distributed under the CC BY Attribution 4.0 International license. Inhibition of Bitter Taste from Oral Tenofovir Alafenamide s Erik Schwiebert,2 Yi Wang,1,2 Ranhui Xi, Katarzyna Choma, John Streiff, Linda J. Flammer, Natasha Rivers, Mehmet Hakan Ozdener, Robert F. Margolskee, Carol M. Christensen, Nancy E. Rawson, Peihua Jiang, and Paul A. S. Breslin Discovery Biomed, Birmingham, Alabama (E.S., J.S.); Monell Chemical Senses Center, Philadelphia, Pennsylvania (Y.W., R.X., K.C., L.J.F., N.R., M.H.O., R.F.M., C.M.C., N.E.R., P.J., P.A.S.B.); and Department of Nutritional Sciences, Rutgers University, New Brunswick, New Jersey (P.A.S.B.) Received May 14, 2020; accepted March 1, 2021 Downloaded from ABSTRACT Children have difficulty swallowing capsules. Yet, when pre- 16 subjects showed reduction in perceived bitterness of TAF sented with liquid formulations, children often reject oral med- after pretreating (or “prerinsing”) with 6-methylflavone and ications due to their intense bitterness. Presently, effective mixing 6-methylflavone with TAF. Bitterness was completely strategies to identify methods, reagents, and tools to block and reliably blocked in two of these subjects. These data molpharm.aspetjournals.org bitterness remain elusive. For a specific bitter-tasting drug, demonstrate that a combined approach of human taste cell identification of the responsible bitter receptors and discovery culture–based screening, receptor-specific assays, and hu- of antagonists for those receptors can provide a method to man psychophysical testing can successfully discover mol- block perceived bitterness. -
Genetic Diversity of Bitter Taste Receptor Gene Family in Sichuan Domestic and Tibetan Chicken Populations
c Indian Academy of Sciences RESEARCH ARTICLE Genetic diversity of bitter taste receptor gene family in Sichuan domestic and Tibetan chicken populations YUAN SU, DIYAN LI, UMA GAUR, YAN WANG, NAN WU, BINLONG CHEN, ZHONGXIAN XU, HUADONG YIN, YAODONG HU and QING ZHU∗ Farm Animal Genetic Resources Exploration and Innovation Key Laboratory of Sichuan Province, Sichuan Agricultural University, Chengdu 611130, People’s Republic of China Abstract The sense of bitter taste plays a critical role in animals as it can help them to avoid intake of toxic and harmful substances. Previous research had revealed that chicken has only three bitter taste receptor genes (Tas2r1, Tas2r2 and Tas2r7). To better understand the genetic polymorphisms and importance of bitter taste receptor genes (Tas2rs) in chicken, here, we sequenced Tas2rs of 30 Sichuan domestic chickens and 30 Tibetan chickens. Thirteen single-nucleotide polymorphisms (SNPs) including three nonsynonymous mutations (m.359G>C, m.503C>A and m.583A>G) were detected in Tas2r1 (m. is the abbreviation for mutation); three SNPs were detected in Tas2r2, but none of them were missense mutation; eight SNPs were detected in Tas2r7 including six nonsynonymous substitutions (m.178G>A, m.421A>C, m.787C>T, m.832G>T, m.907A>Tand m.943G>A). Tajima’s D neutral test indicates that there is no population expansion in both populations, and the size of the population is relatively stable. All the three networks indicate that red jungle fowls share haplotypes with domestic chickens. In addition, we found that haplotypes H1 and HE1 were positively associated with high-altitude adaptation, whereas haplotypes H4 and HE4 showed a negative correlation with high-altitude adaptation in Tas2rs. -
Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib
Supplementary Online Content Chen G, McQuade JL, Panka DJ, et al. Clinical, molecular and immune analysis of dabrafenib-trametinib combination treatment for metastatic melanoma that progressed during BRAF inhibitor monotherapy: a phase 2 clinical trial. JAMA Oncology. Published online April 28, 2016. doi:10.1001/jamaoncol.2016.0509. eMethods. eReferences. eTable 1. Clinical efficacy eTable 2. Adverse events eTable 3. Correlation of baseline patient characteristics with treatment outcomes eTable 4. Patient responses and baseline IHC results eFigure 1. Kaplan-Meier analysis of overall survival eFigure 2. Correlation between IHC and RNAseq results eFigure 3. pPRAS40 expression and PFS eFigure 4. Baseline and treatment-induced changes in immune infiltrates eFigure 5. PD-L1 expression eTable 5. Nonsynonymous mutations detected by WES in baseline tumors This supplementary material has been provided by the authors to give readers additional information about their work. © 2016 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/30/2021 eMethods Whole exome sequencing Whole exome capture libraries for both tumor and normal samples were constructed using 100ng genomic DNA input and following the protocol as described by Fisher et al.,3 with the following adapter modification: Illumina paired end adapters were replaced with palindromic forked adapters with unique 8 base index sequences embedded within the adapter. In-solution hybrid selection was performed using the Illumina Rapid Capture Exome enrichment kit with 38Mb target territory (29Mb baited). The targeted region includes 98.3% of the intervals in the Refseq exome database. Dual-indexed libraries were pooled into groups of up to 96 samples prior to hybridization.